vs
Embecta Corp.（EMBC）与Forestar Group Inc.（FOR）财务数据对比。点击上方公司名可切换其他公司
Forestar Group Inc.的季度营收约是Embecta Corp.的1.0倍（$273.0M vs $261.2M），Embecta Corp.净利率更高（16.9% vs 5.6%，领先11.2%），Forestar Group Inc.同比增速更快（9.0% vs -0.3%），Embecta Corp.自由现金流更多（$16.6M vs $-157.1M），过去两年Embecta Corp.的营收复合增速更高（-4.6% vs -9.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
EMBC vs FOR — 直观对比
营收规模更大
FOR
是对方的1.0倍
$261.2M
营收增速更快
FOR
高出9.3%
-0.3%
净利率更高
EMBC
高出11.2%
5.6%
自由现金流更多
EMBC
多$173.7M
$-157.1M
两年增速更快
EMBC
近两年复合增速
-9.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $273.0M |
| 净利润 | $44.1M | $15.4M |
| 毛利率 | 61.9% | 20.1% |
| 营业利润率 | 31.9% | 7.6% |
| 净利率 | 16.9% | 5.6% |
| 营收同比 | -0.3% | 9.0% |
| 净利润同比 | — | -6.7% |
| 每股收益（稀释后） | $0.74 | $0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCFOR
| Q4 25 | $261.2M | $273.0M | ||
| Q3 25 | $264.0M | $670.5M | ||
| Q2 25 | $295.5M | $390.5M | ||
| Q1 25 | $259.0M | $351.0M | ||
| Q4 24 | $261.9M | $250.4M | ||
| Q3 24 | $286.1M | $551.3M | ||
| Q2 24 | $272.5M | $318.4M | ||
| Q1 24 | $287.2M | $333.8M |
净利润EMBCFOR
| Q4 25 | $44.1M | $15.4M | ||
| Q3 25 | $26.4M | $86.9M | ||
| Q2 25 | $45.5M | $32.9M | ||
| Q1 25 | $23.5M | $31.6M | ||
| Q4 24 | $0 | $16.5M | ||
| Q3 24 | $14.6M | $81.5M | ||
| Q2 24 | $14.7M | $38.7M | ||
| Q1 24 | $28.9M | $45.0M |
毛利率EMBCFOR
| Q4 25 | 61.9% | 20.1% | ||
| Q3 25 | 60.0% | 22.3% | ||
| Q2 25 | 66.7% | 20.4% | ||
| Q1 25 | 63.4% | 22.6% | ||
| Q4 24 | 60.0% | 22.0% | ||
| Q3 24 | 60.7% | 23.9% | ||
| Q2 24 | 69.8% | 22.5% | ||
| Q1 24 | 64.6% | 24.9% |
营业利润率EMBCFOR
| Q4 25 | 31.9% | 7.6% | ||
| Q3 25 | 21.4% | 16.9% | ||
| Q2 25 | 31.8% | 11.2% | ||
| Q1 25 | 24.3% | 11.6% | ||
| Q4 24 | 11.0% | 8.7% | ||
| Q3 24 | 9.2% | 19.7% | ||
| Q2 24 | 20.5% | 16.2% | ||
| Q1 24 | 13.6% | 17.6% |
净利率EMBCFOR
| Q4 25 | 16.9% | 5.6% | ||
| Q3 25 | 10.0% | 13.0% | ||
| Q2 25 | 15.4% | 8.4% | ||
| Q1 25 | 9.1% | 9.0% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | 5.1% | 14.8% | ||
| Q2 24 | 5.4% | 12.2% | ||
| Q1 24 | 10.1% | 13.5% |
每股收益（稀释后）EMBCFOR
| Q4 25 | $0.74 | $0.30 | ||
| Q3 25 | $0.44 | $1.70 | ||
| Q2 25 | $0.78 | $0.65 | ||
| Q1 25 | $0.40 | $0.62 | ||
| Q4 24 | $0.00 | $0.32 | ||
| Q3 24 | $0.24 | $1.59 | ||
| Q2 24 | $0.25 | $0.76 | ||
| Q1 24 | $0.50 | $0.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $211.7M |
| 总债务越低越好 | — | $793.2M |
| 股东权益账面价值 | $-613.1M | $1.8B |
| 总资产 | $1.1B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.44× |
8季度趋势，按日历期对齐
现金及短期投资EMBCFOR
| Q4 25 | $201.3M | $211.7M | ||
| Q3 25 | $225.5M | $379.2M | ||
| Q2 25 | $230.6M | $189.2M | ||
| Q1 25 | $209.3M | $174.3M | ||
| Q4 24 | $210.0M | $132.0M | ||
| Q3 24 | $267.5M | $481.2M | ||
| Q2 24 | $275.1M | $359.2M | ||
| Q1 24 | $299.8M | $416.2M |
总债务EMBCFOR
| Q4 25 | — | $793.2M | ||
| Q3 25 | $1.4B | $802.7M | ||
| Q2 25 | — | $872.8M | ||
| Q1 25 | — | $872.5M | ||
| Q4 24 | — | $806.8M | ||
| Q3 24 | $1.6B | $706.4M | ||
| Q2 24 | — | $706.1M | ||
| Q1 24 | — | $705.7M |
股东权益EMBCFOR
| Q4 25 | $-613.1M | $1.8B | ||
| Q3 25 | $-650.6M | $1.8B | ||
| Q2 25 | $-669.6M | $1.7B | ||
| Q1 25 | $-736.2M | $1.6B | ||
| Q4 24 | $-768.8M | $1.6B | ||
| Q3 24 | $-738.3M | $1.6B | ||
| Q2 24 | $-763.7M | $1.5B | ||
| Q1 24 | $-769.6M | $1.5B |
总资产EMBCFOR
| Q4 25 | $1.1B | $3.2B | ||
| Q3 25 | $1.1B | $3.1B | ||
| Q2 25 | $1.2B | $3.1B | ||
| Q1 25 | $1.1B | $3.0B | ||
| Q4 24 | $1.1B | $3.0B | ||
| Q3 24 | $1.3B | $2.8B | ||
| Q2 24 | $1.3B | $2.7B | ||
| Q1 24 | $1.2B | $2.6B |
负债/权益比EMBCFOR
| Q4 25 | — | 0.44× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.47× | ||
| Q1 24 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $-157.0M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $-157.1M |
| 自由现金流率自由现金流/营收 | 6.4% | -57.5% |
| 资本支出强度资本支出/营收 | 0.2% | 0.0% |
| 现金转化率经营现金流/净利润 | 0.39× | -10.19× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $93.0M |
8季度趋势，按日历期对齐
经营现金流EMBCFOR
| Q4 25 | $17.2M | $-157.0M | ||
| Q3 25 | $84.0M | $256.3M | ||
| Q2 25 | $81.2M | $15.8M | ||
| Q1 25 | $31.8M | $-19.8M | ||
| Q4 24 | $-5.3M | $-450.0M | ||
| Q3 24 | $26.6M | $119.2M | ||
| Q2 24 | $-2.1M | $-61.7M | ||
| Q1 24 | $24.3M | $-59.2M |
自由现金流EMBCFOR
| Q4 25 | $16.6M | $-157.1M | ||
| Q3 25 | $76.7M | $255.6M | ||
| Q2 25 | $80.8M | $15.0M | ||
| Q1 25 | $31.7M | $-20.5M | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | — | $118.4M | ||
| Q2 24 | $-11.8M | $-62.3M | ||
| Q1 24 | $20.9M | $-59.8M |
自由现金流率EMBCFOR
| Q4 25 | 6.4% | -57.5% | ||
| Q3 25 | 29.1% | 38.1% | ||
| Q2 25 | 27.3% | 3.8% | ||
| Q1 25 | 12.2% | -5.8% | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | — | 21.5% | ||
| Q2 24 | -4.3% | -19.6% | ||
| Q1 24 | 7.3% | -17.9% |
资本支出强度EMBCFOR
| Q4 25 | 0.2% | 0.0% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.6% | 0.0% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 3.6% | 0.2% | ||
| Q1 24 | 1.2% | 0.2% |
现金转化率EMBCFOR
| Q4 25 | 0.39× | -10.19× | ||
| Q3 25 | 3.18× | 2.95× | ||
| Q2 25 | 1.78× | 0.48× | ||
| Q1 25 | 1.35× | -0.63× | ||
| Q4 24 | — | -27.27× | ||
| Q3 24 | 1.82× | 1.46× | ||
| Q2 24 | -0.14× | -1.59× | ||
| Q1 24 | 0.84× | -1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
